SCHD: Why I'm Still Buying After Strong 2026 Performance

This is less a stock-specific call than a factor expression: SCHD is a low-duration quality cash-return basket, so the upside is mostly in multiple support if rates stay range-bound or drift lower. The embedded healthcare tilt is the key second-order edge; ABT and MRK are the cleanest beneficiaries of investors paying for steady free-cash-flow conversion and dividend growth, while UNH adds operating leverage but also the most idiosyncratic headline risk. The structural loser is still high-multiple growth, because a dividend basket with limited IT exposure only outperforms materially when breadth improves away from the mega-cap concentration trade.

The main catalyst window is 1-3 months and lives in macro: Treasury volatility, Fed repricing, and quarter-end factor flows. If the 10Y backs up or QQQ keeps widening its lead on AI/earnings momentum, SCHD likely underperforms even if fundamentals are fine. Over 6-18 months, the setup improves if earnings growth plus dividend growth can compound faster than inflation, but this is a defensive compounding story, not a rapid re-rating story.

Contrarian view: the market may be underestimating how much cash-return screens can outperform in a high-dispersion tape, especially if equity volatility stays elevated and investors rotate toward balance-sheet certainty. The flip side is that if growth leadership broadens, SCHD becomes a respectable but capped-return vehicle rather than a source of true alpha. The thesis would be falsified by persistent new highs in QQQ, a renewed rise in real yields, or a healthcare policy/regulatory shock hitting UNH and the broader defensive complex.